Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - 28/08/11
Doi : 10.1016/j.amjcard.2003.06.009
Gregory G Schwartz, MD, PhD a, ⁎ 
, Peter Ganz, MD b, David Waters, MD c, Steve Arikian, MD d
, Peter Ganz, MD b, David Waters, MD c, Steve Arikian, MD d a Veterans Administration Medical Center and University of Colorado Health Sciences Center, Denver, Colorado, USA
b Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
c San Francisco General Hospital and University of California, San Francisco, California, USA
d The Analytica Group, Ltd, and The Joseph L. Mailman School of Public Health, Columbia University, New York, New York, USA
*Dr. Schwartz's address is: Cardiology Section 111B, VA Medical Center, 1055 Clermont St, Denver, Colorado 80220, USA.
Abstract |
An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was $157/patient with a cost-effectiveness ratio of $4,086/event avoided.
Le texte complet de cet article est disponible en PDF. | This research was supported by Pfizer, Inc., New York, New York. |
© 2003
Excerpta Medica Inc. Tous droits réservés.
Vol 92 - N° 9
P. 1109-1112 - novembre 2003 Retour au numéro
Article précédent
- Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population
- Branko Kopjar, Anne E.B. Sales, Sandra L. Piñeros, Haili Sun, Yu-Fang Li, Ashley N. Hedeen
- Effect of pretreatment vitamin d levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia
- Kouji Kajinami, Noboru Takekoshi, Shinobu Matsui, Seiyu Kanemitsu, Shinji Okubo, Sugako Kanayama, Naohiro Yamashita, Ryoko Sato
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?